523:
29:
430:
Harrison, Stephen A.; Alkhouri, Naim; Davison, Beth A.; Sanyal, Arun; Edwards, Christopher; Colca, Jerry R.; Lee, Bo Hyun; Loomba, Rohit; Cusi, Kenneth; Kolterman, Orville; Cotter, Gad; Dittrich, Howard C. (April 2020). "Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized,
394:
Colca, Jerry R.; Lee, Bo Hyun; Iwashita, Julie S.; Dittrich, Howard C.; Harrison, Stephen A. (1 June 2020). "1090-P: MSDC-0602k, a New Oral
Insulin Sensitizer in Insulin Resistant NASH Patients with and without Type 2 Diabetes (T2D)".
588:
282:
296:
564:
583:
598:
324:
InChI=1S/C19H17NO5S/c1-24-15-4-2-3-13(10-15)16(21)11-25-14-7-5-12(6-8-14)9-17-18(22)20-19(23)26-17/h2-8,10,17H,9,11H2,1H3,(H,20,22,23)
468:"Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide"
367:
316:
362:
binding. It is hoped to have fewer adverse effects than the thiazolidinediones and is being developed by Cirius
Therapeutics for
78:
54:
355:
466:
Kamm, Dakota R.; Pyles, Kelly D.; Sharpe, Martin C.; Healy, Laura N.; Colca, Jerry R.; McCommis, Kyle S. (January 2021).
180:
613:
593:
557:
608:
209:
550:
95:
412:
347:
499:
448:
351:
169:
104:
603:
489:
479:
440:
404:
374:
225:
189:
363:
534:
494:
467:
577:
416:
129:
530:
444:
20:
484:
359:
258:
160:
371:
28:
503:
452:
522:
140:
408:
149:
115:
200:
589:
Experimental drugs developed for non-alcoholic fatty liver disease
281:
272:
538:
431:double-blind, placebo-controlled phase IIb study".
304:
COC1=CC=CC(=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
270:
257:
224:
219:
199:
179:
159:
139:
114:
94:
69:
53:
48:
40:
35:
128:
103:
44:Azemiglitazone potassium; MSDC-0602; MSDC-0602K
558:
8:
19:
86:5-phenyl]methyl]-1,3-thiazolidine-2,4-dione
565:
551:
168:
27:
493:
483:
377:, azemiglitazone potassium (MSDC-0602K).
188:
386:
321:
301:
148:
83:
18:
208:
7:
519:
517:
119:
14:
368:non-alcoholic fatty liver disease
350:designed to retain the effect of
521:
242:
236:
472:Journal of Biological Chemistry
356:mitochondrial pyruvate carriers
329:Key:YAUMOGALQJYOJQ-UHFFFAOYSA-N
251:
245:
230:
1:
537:. You can help Knowledge by
584:Experimental diabetes drugs
370:. It is formulated as its
630:
516:
445:10.1016/j.jhep.2019.10.023
220:Chemical and physical data
599:3-Methoxyphenyl compounds
485:10.1016/j.jbc.2021.100807
312:
292:
74:
26:
533:-related article is a
433:Journal of Hepatology
409:10.2337/db20-1090-P
23:
614:Pharmacology stubs
594:Thiazolidinediones
352:thiazolidinediones
348:insulin sensitizer
546:
545:
337:
336:
283:Interactive image
16:Chemical compound
621:
567:
560:
553:
525:
518:
508:
507:
497:
487:
463:
457:
456:
427:
421:
420:
403:(Supplement_1).
391:
285:
265:
253:
247:
244:
238:
232:
212:
192:
172:
152:
132:
122:
121:
107:
31:
24:
22:
629:
628:
624:
623:
622:
620:
619:
618:
609:Aromatic ethers
574:
573:
572:
571:
514:
512:
511:
465:
464:
460:
429:
428:
424:
393:
392:
388:
383:
364:type 2 diabetes
333:
330:
325:
320:
319:
308:
305:
300:
299:
288:
263:
250:
241:
235:
215:
195:
175:
155:
135:
118:
110:
90:
87:
82:
81:
65:
62:Investigational
17:
12:
11:
5:
627:
625:
617:
616:
611:
606:
601:
596:
591:
586:
576:
575:
570:
569:
562:
555:
547:
544:
543:
526:
510:
509:
458:
439:(4): 613–626.
422:
385:
384:
382:
379:
340:Azemiglitazone
335:
334:
332:
331:
328:
326:
323:
315:
314:
313:
310:
309:
307:
306:
303:
295:
294:
293:
290:
289:
287:
286:
278:
276:
268:
267:
261:
255:
254:
248:
239:
233:
228:
222:
221:
217:
216:
214:
213:
205:
203:
197:
196:
194:
193:
185:
183:
177:
176:
174:
173:
165:
163:
157:
156:
154:
153:
145:
143:
137:
136:
134:
133:
125:
123:
112:
111:
109:
108:
100:
98:
92:
91:
89:
88:
85:
77:
76:
75:
72:
71:
67:
66:
64:
63:
59:
57:
51:
50:
46:
45:
42:
38:
37:
33:
32:
21:Azemiglitazone
15:
13:
10:
9:
6:
4:
3:
2:
626:
615:
612:
610:
607:
605:
602:
600:
597:
595:
592:
590:
587:
585:
582:
581:
579:
568:
563:
561:
556:
554:
549:
548:
542:
540:
536:
532:
527:
524:
520:
515:
505:
501:
496:
491:
486:
481:
477:
473:
469:
462:
459:
454:
450:
446:
442:
438:
434:
426:
423:
418:
414:
410:
406:
402:
398:
390:
387:
380:
378:
376:
373:
369:
365:
361:
358:with limited
357:
353:
349:
346:) is a novel
345:
341:
327:
322:
318:
311:
302:
298:
291:
284:
280:
279:
277:
274:
269:
262:
260:
256:
229:
227:
223:
218:
211:
210:ChEMBL4291468
207:
206:
204:
202:
198:
191:
187:
186:
184:
182:
178:
171:
167:
166:
164:
162:
158:
151:
147:
146:
144:
142:
138:
131:
127:
126:
124:
117:
113:
106:
102:
101:
99:
97:
93:
84:
80:
73:
68:
61:
60:
58:
56:
52:
47:
43:
39:
36:Clinical data
34:
30:
25:
539:expanding it
531:pharmacology
528:
513:
475:
471:
461:
436:
432:
425:
400:
396:
389:
343:
339:
338:
105:1133819-87-0
55:Legal status
49:Legal status
266: g·mol
70:Identifiers
41:Other names
578:Categories
478:: 100807.
381:References
360:PPAR-gamma
271:3D model (
259:Molar mass
190:81MXZ6QOBM
161:ChemSpider
96:CAS Number
79:IUPAC name
417:225824217
372:potassium
344:MSDC-0602
504:34022222
453:31697972
397:Diabetes
170:32698412
141:DrugBank
130:25230266
604:Ketones
495:8192871
226:Formula
150:DB16028
116:PubChem
502:
492:
451:
415:
297:SMILES
264:371.41
201:ChEMBL
529:This
413:S2CID
317:InChI
273:JSmol
535:stub
500:PMID
449:PMID
375:salt
366:and
181:UNII
490:PMC
480:doi
476:296
441:doi
405:doi
354:on
120:CID
580::
498:.
488:.
474:.
470:.
447:.
437:72
435:.
411:.
401:69
399:.
240:17
234:19
566:e
559:t
552:v
541:.
506:.
482::
455:.
443::
419:.
407::
342:(
275:)
252:S
249:5
246:O
243:N
237:H
231:C
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
